Seizures and coma were not predictors of long-term outcomes.
Prior studies have detailed the lengthy but optimistic recovery following anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDA-E; NEJM JW Neurol 2019 Jan 30 and Neurology 2019; 92:e244). To test potential predictors of outcomes in these patients, investigators conducted a retrospective study of 38 patients with anti-NMDAR-E from a single center, using the modified Rankin Scale (mRS) and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE). CASE measures clinical severity factors including seizures, memory dysfunction, psychiatric symptoms, level of consciousness, language, movement, gait, brainstem dysfunction, and weakness.
At short-term follow-up (median, 10 weeks), worse outcomes were associated with baseline dysautonomia…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)